Zenlabs Ethica Ltd
₹ 41.0
-0.02%
24 Apr
- close price
About
Incorporated in 1993, Zenlabs Ethica Ltd is engaged in trading, marketing and distribution of pharmaceutical formulations.
Key Points
- Market Cap ₹ 26.7 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 70.0 / 31.3
- Stock P/E 59.3
- Book Value ₹ 15.1
- Dividend Yield 0.61 %
- ROCE 12.4 %
- ROE 9.46 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.71 times its book value
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.14%
- The company has delivered a poor sales growth of -0.86% over past five years.
- Company has a low return on equity of 9.30% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.59 | 0.00 | 0.00 | 0.00 | 15.09 | 78.73 | 69.85 | 65.37 | 58.50 | 56.64 | 69.09 | 66.89 | 57.83 | |
| 4.64 | 0.15 | 0.04 | 0.05 | 14.89 | 77.28 | 68.00 | 63.28 | 59.20 | 54.89 | 66.70 | 63.99 | 55.69 | |
| Operating Profit | -1.05 | -0.15 | -0.04 | -0.05 | 0.20 | 1.45 | 1.85 | 2.09 | -0.70 | 1.75 | 2.39 | 2.90 | 2.14 |
| OPM % | -29.25% | 1.33% | 1.84% | 2.65% | 3.20% | -1.20% | 3.09% | 3.46% | 4.34% | 3.70% | |||
| 0.00 | 0.10 | 0.00 | 0.00 | -0.03 | 0.08 | 0.10 | 0.10 | 0.05 | 0.11 | 0.09 | -0.45 | -0.27 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.10 | 0.09 | 0.07 | 0.23 | 0.29 | 0.37 | 0.53 | 0.73 |
| Depreciation | 0.02 | 0.02 | 0.01 | 0.01 | 0.06 | 0.20 | 0.20 | 0.23 | 0.29 | 0.71 | 0.89 | 1.25 | 1.28 |
| Profit before tax | -1.07 | -0.07 | -0.05 | -0.06 | 0.09 | 1.23 | 1.66 | 1.89 | -1.17 | 0.86 | 1.22 | 0.67 | -0.14 |
| Tax % | 0.00% | 0.00% | 0.00% | -16.67% | -88.89% | 21.95% | 29.52% | 32.80% | 36.75% | 10.47% | 36.07% | 26.87% | |
| -1.07 | -0.07 | -0.06 | -0.07 | 0.17 | 0.95 | 1.16 | 1.26 | -0.73 | 0.77 | 0.78 | 0.49 | -0.12 | |
| EPS in Rs | -2.82 | -0.18 | -0.16 | -0.18 | 0.26 | 1.46 | 1.78 | 1.94 | -1.12 | 1.18 | 1.20 | 0.75 | -0.18 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 16.32% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 33.21% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | 5% |
| TTM: | -13% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | -5% |
| 3 Years: | 48% |
| TTM: | -51% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -5% |
| 3 Years: | 18% |
| 1 Year: | -20% |
| Return on Equity | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 7% |
| 3 Years: | 9% |
| Last Year: | 9% |
Balance Sheet
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.62 | 3.62 | 3.62 | 3.62 | 6.20 | 6.20 | 6.20 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 | 6.51 |
| Reserves | -1.45 | -1.51 | -1.57 | -1.65 | -1.41 | -0.41 | 0.81 | 1.77 | 0.90 | 2.05 | 2.82 | 3.19 | 3.34 |
| 0.00 | 0.00 | 0.00 | 0.00 | 1.09 | 0.96 | 0.85 | 0.60 | 0.73 | 2.60 | 3.90 | 5.85 | 8.66 | |
| 1.89 | 1.75 | 1.75 | 1.77 | 24.49 | 26.62 | 21.96 | 26.01 | 25.85 | 21.04 | 24.66 | 27.95 | 21.11 | |
| Total Liabilities | 4.06 | 3.86 | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 39.62 |
| 0.12 | 0.10 | 0.09 | 0.06 | 1.68 | 1.50 | 1.33 | 1.36 | 1.12 | 3.51 | 3.53 | 5.02 | 4.34 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 1.25 | 0.95 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 | 0.70 |
| 3.94 | 3.76 | 3.71 | 3.68 | 27.44 | 30.92 | 27.79 | 32.83 | 32.17 | 27.99 | 33.66 | 37.78 | 34.58 | |
| Total Assets | 4.06 | 3.86 | 3.80 | 3.74 | 30.37 | 33.37 | 29.82 | 34.89 | 33.99 | 32.20 | 37.89 | 43.50 | 39.62 |
Cash Flows
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | 0.00 | -0.01 | 0.02 | 0.92 | -1.06 | 0.36 | 0.80 | 0.45 | -8.41 | -0.38 | 1.52 | |
| 0.00 | 0.00 | 0.00 | 0.00 | -1.69 | -0.02 | -0.03 | -0.22 | 0.01 | 0.15 | 0.00 | -1.47 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 3.23 | -0.27 | -0.23 | -0.14 | -0.03 | -0.52 | 0.31 | 0.06 | |
| Net Cash Flow | -0.24 | 0.00 | -0.01 | 0.02 | 2.47 | -1.35 | 0.09 | 0.44 | 0.43 | -8.78 | -0.07 | 0.11 |
Ratios
Figures in Rs. Crores
| Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 55.92 | 398.14 | 107.65 | 126.40 | 139.37 | 138.76 | 121.67 | 109.57 | 118.41 | |||
| Inventory Days | 119.31 | 249.62 | 34.42 | 11.12 | 31.23 | 33.95 | 40.46 | 56.05 | 77.85 | |||
| Days Payable | 166.15 | 665.46 | 136.41 | 125.88 | 161.27 | 165.31 | 150.28 | 141.30 | 174.04 | |||
| Cash Conversion Cycle | 9.08 | -17.70 | 5.66 | 11.64 | 9.33 | 7.40 | 11.85 | 24.32 | 22.21 | |||
| Working Capital Days | 201.31 | 4.84 | 13.95 | 23.36 | 28.42 | 24.02 | 32.48 | 44.96 | 50.37 | |||
| ROCE % | -39.56% | -3.27% | -2.40% | -2.99% | 9.94% | 21.06% | 23.96% | 24.13% | -11.05% | 12.02% | 13.04% | 12.37% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Demise
2d - Of Sad Demises of Mr. Jasbir Singh Kalra (Person under Promoter Group) under Reg 30 & Reg 31A (6)(c) of SEBI LODR Regulations 2015
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 18 Apr
- Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 15 Apr
- Compliance Certificate By PCS As Per Reg 40(9) & (10) Of SEBI LODR Regulations 2015 12 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Compliance Certificate as per Reg. 74(5) of SEBI (DP) Regulations 2018
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2009
from bse
-
Financial Year 2008
from bse
Business Overview:[1]
Zenlabs Ethica Ltd is a WHO-GMP certified, third party manufacturing pharma company. Company was launched in collaboration with Zenlabs Pharmaceutical Inc, Canada. It is a part of Preet Remedies Group which has five manufacturing units namely Preet Remedies Pvt. Ltd., Oasis Pharma & Phytomolecules Pvt. Ltd., Quixotic Healthcare Unit I & II, and Alpha Products. At any of these facilities, minimum order quantity offered is 2000 boxes of drugs.